AgeX, University of California Partner on Huntington’s Disease Research

- February 3rd, 2020

AgeX is teaming up with the University of California to develop treatments for neurological disorders for which there are no cures.

AgeX Therapeutics (NYSE American:AGE) is teaming up with the University of California, Irvine (UCI) to use AgeX’s PureStem technology with the goal of developing treatments for neurological disorders and diseases for which there are no cures.

As quoted in the press release:

The collaboration’s initial R&D work, expected to take approximately one year, will be conducted in the UCI laboratory of Leslie Thompson, PhD, Chancellor’s Professor of Psychiatry & Human Behavior and Neurobiology & Behavior, a leading researcher in the field of Huntington’s disease and other neurological disorders, under a Sponsored Research Agreement handled by the Industry Sponsored Research team at UCI Beall Applied Innovation. The initial focus will be on Huntington’s disease, while other potential targets may include Parkinson’s, Alzheimer’s, and stroke.

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

Read our FREE outlook report below!

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply